Immucor

Immucor Q1 profit rises

The Atlanta Business Chronicle (Free subscription) | 01/10/2008

Immucor Inc. hit record quarterly profitability and revenue in the first quarter of fiscal 2009.

Immucor Announces Record Fiscal First Quarter Results

PR News Wire (Free subscription) | 01/10/2008

NORCROSS, Ga., Oct. 1 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for the fiscal first quarter ended August 31, 2008. Our first quarter 2009 results include the results of BioArray Solutions beginning August 4, 2008, the date the acquisition was consummated. ...

Zacks Analyst Interview Highlights: Cepheid, BioSphere Medical and Immucor

Business Wire (Free subscription) | 06/08/2008

CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Tom Park, who discusses Cepheid

• Zacks Analyst Interview Highlights: Cepheid, BioSphere Medical and Immucor - The Earth Times Online Newspaper

Immucor Closes BioArray Acquisition

Red Orbit (Free subscription) | 05/08/2008

NORCROSS, Ga., Aug. 5 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has closed its previously-announced acquisition of BioArray Solutions Ltd.

• Immucor Closes BioArray Acquisition - PR News Wire

Zacks Earnings and Margins Strategy highlights: Immucor, Central European Distribution, Greif and KapStone Paper and Packaging.

Business Wire (Free subscription) | 28/07/2008

CHICAGO--(BUSINESS WIRE)--Earnings are the single most important metric for a company. Combine that with a healthy Net Profit Margin and you find a screen that has generated a cumulative

Immucor, Inc. Adds Board Members

Red Orbit (Free subscription) | 25/07/2008

NORCROSS, GA., July 25 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that Dr. Paul V. Holland, James F. Clouser and Chris E.

• Immucor, Inc. Adds Board Members - The Earth Times Online Newspaper
• Immucor, Inc. Adds Board Members - PR News Wire

Immucor sets record profit in fiscal 2008

The Atlanta Business Chronicle (Free subscription) | 23/07/2008

Blood reagent systems maker Immucor Inc. (NASDAQ: BLUD) reported Wednesday its profit increased 19 percent in fiscal 2008. (BLUD)

Immucor Announces Record Year End and Fiscal Fourth Quarter Results

PR News Wire (Free subscription) | 23/07/2008

NORCROSS, Ga., July 23 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for the fiscal fourth quarter and year ended May 31, 2008. "We are very pleased with our fiscal 2008 financial performance and the record results achieved for revenues, net income and earnings...

Immucor Inc. (BLUD): Ron Baron Adds to His Holdings in BLUD

GuruFocus Updates (Free subscription) | 14/06/2008

Ron Baron added to his holdings in Medical Equipment company Immucor Inc. (BLUD) during the 3-months ended 2008-03-31 by 24.69%. His purchase prices were between $ 21.25 and $ 33.68, with an estimated average price of $ 27.7. The impact to his portfolio due to this purchase was 0.05 %. His holdings was 2010250 shares as of 2008-03-31. As of last market close, the price of Immucor Inc. (BLUD) was $...

FDA Accepts Immucor's Response to Warning Letter

Red Orbit (Free subscription) | 06/06/2008

NORCROSS, Ga., June 6 /PRNewswire-FirstCall/ -- Immucor, Inc., , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced that today the FDA notified the company that it has reviewed Immucor's response to the previously-reported warning letter, and Immucor's proposed corrective actions appear to be adequate.

FDA Accepts Immucor's Response to Warning Letter

PR News Wire (Free subscription) | 06/06/2008

NORCROSS, Ga., June 6 /PRNewswire-FirstCall/ -- Immucor, Inc., (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced that today the FDA notified the company that it has reviewed Immucor's response to the previously-reported warning letter, and Immucor's proposed corrective actions appear to be adequate. The FDA stated it would...

Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance

Red Orbit (Free subscription) | 05/06/2008

NORCROSS, Ga., June 4 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced revenue and earnings guidance for the fiscal year ending May 31, 2009.

• Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance - PR News Wire

Immucor gives 2009 profit forecast

Market Watch (Free subscription) | 04/06/2008

NEW YORK (MarketWatch) -- Immucor Inc. said Wednesday that it expects to post a profit of $1.11 to $1.15 a share in fiscal 2009 on revenue of $292 million to $300 million. The Norcross, Ga.-based blood transfusion systems company said its forecast excludes the impact of the pending BioArray acquisition, which will result in earnings dilution of about 20 to 23 cents a share in the first full year of...

• Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance - PR News Wire

FDA sends warning to Immucor

The Atlanta Business Chronicle (Free subscription) | 13/05/2008

The U.S. Food and Drug Administration has issued a warning letter to Immucor Inc. over alleged problems with its manufacturing process. (BLUD)

Immucor Responding to FDA Warning Letter

PR News Wire (Free subscription) | 13/05/2008

NORCROSS, Ga., May 13 /PRNewswire-FirstCall/ -- Immucor, Inc., (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today it is responding to an FDA warning letter posted today on the FDA website (). Immucor CEO Dr. Gioacchino De Chirico said: "Our industry is highly regulated by the FDA, and we are subject to periodic inspection...